945,1,Syria, Travel Ban, Kabul: Your Morning Briefing - The New York Times
2148,1,F.D.A. Nominee, Paid Millions by Industry, Says He’ll Recuse Himself if Needed - The New York Times
2288,1,Fox Losing More Advertisers After Sexual Harassment Claims Against O’Reilly - The New York Times
3771,1,Mylan Tries Again to Quell Pricing Outrage by Offering Generic EpiPen - The New York Times
5077,1,New Ebola Vaccine Gives 100 Percent Protection - The New York Times
5770,1,The EpiPen, a Case Study in Health System Dysfunction - The New York Times
31802,1,The search for what triggers type 1 diabetes
33719,3,When $65,000 a year for a drug is applauded
36722,1,Now 41 US military members have contracted Zika
42192,1,Cholesterol-lowering drugs get FDA advisory approval
44775,1,Insiders reveal how Boston moved to the forefront of the global fight against deadly diseases
44923,2,Nevada is close to passing a landmark bill to tackle high drug prices
46735,7,A new multibillion-pound deal is brewing in the pharma industry
48185,2,Pfizer is reportedly close to spending $14 billion on cancer drugmaker Medivation
48389,4,The world is facing a growing snakebite crisis — and there’s a serious shortage of antivenom
48461,3,Verily and Sanofi just launched a new company to tackle diabetes care
48538,3,There’s something odd about the way insulin prices change
49593,1,Here’s the presentation David Einhorn just gave to a room of elite hedge fund managers